Unlocking the future of biopharma: Next-gen RNA delivery & smarter formulations with Croda Pharma

Date: 23 – 24 June 2025
Location: Basel, Switzerland
Booth: Zone A - 26

Join Croda Pharma and Avanti Research at Discovery & Development Europe 2025 in Switzerland, where innovation meets real-world application. We’re excited to share pioneering insights on RNA therapeutic delivery and biopharmaceutical formulation - designed to help you solve your most pressing drug development challenges. Don’t miss our speaker sessions where we’ll unveil how advanced lipid technologies are redefining RNA delivery, and explore the evolving role of detergents in protein stabilisation. Let’s connect at booth 26 in Zone A to discuss how our high-purity excipients, lipids, vaccine adjuvants, and bioprocessing solutions can accelerate your next breakthrough from concept to commercialisation.

Unable to attend? Request our presentations here.

Next-Generation Lipid Innovations Transforming RNA Therapeutic Delivery

Monday 23 June, 14:00, RNA Design and Delivery track

Lipid-based delivery systems are revolutionising the development of nucleic acid therapeutics, offering unmatched potential to address complex biological challenges. Yet as the field accelerates, so do its demands - calling for greater stability, reduced immunogenicity, and targeted delivery beyond the liver. Traditional lipid nanoparticles (LNPs) excel at hepatic targeting, but unlocking access to other tissues requires fresh innovation. Delivery success also hinges on the unique size and type of each nucleic acid payload, demanding precision-engineered solutions.

Join us to explore how the Avanti Research and GMP Avanti lipid portfolios are redefining what’s possible in drug delivery. Discover how our cutting-edge lipid technologies are overcoming today's most pressing barriers - empowering researchers to design next-generation RNA delivery platforms with greater specificity, stability, and therapeutic impact. Don’t miss this opportunity to gain insights that could accelerate your nucleic acid development programs.

Polysorbates and beyond: Exploring detergent strategy in biologic drug formulation

Monday 23 June, 14:50, Large Molecule Delivery Track

Detergents remain commonplace in the majority of biotherapeutic formulations, with polysorbate remaining the mainstay of most protein-based formulation acting as key ingredients to prevent physical aggregation, however, research which has accelerated over the last couple of decades has gradually revealed various aspects of polysorbate which need to be understood and controlled. These include degradation via oxidative and enzymatic mechanisms, other forms of loss from surface adhesion and in-process interactions and investigating the interplay of protein, interfaces and detergent. These studies have also expanded in exploring alternatives to polysorbates to see if they can offer the stabilising benefits to the protein without such degradation and loss complexities. In this talk we shall first take a step back to summarise what is known on the performance attributes both positive and negative for polysorbates and studied alternatives. Then we shall switch the focus to what questions still need to be answered to ascertain what would be an optimal stabilising detergent for protein biotherapeutics and what still needs to answered to understand and manage risk.